Nicholson C. David 4
4 · Allergan plc · Filed Oct 30, 2017
Insider Transaction Report
Form 4
Allergan plcAGN
Nicholson C. David
Chief R&D Officer
Transactions
- Exercise/Conversion
Ordinary Shares, par value $0.0001
2017-10-26+6,274→ 19,314 total - Exercise/Conversion
Performance Based Restricted Share Unit
2017-10-26−6,274→ 0 total→ Ordinary Shares (6,274 underlying)
Footnotes (3)
- [F1]The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019.
- [F2]Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.
- [F3]Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.